Area of Research: Drug Resistance

2022 Grant Recipients

• Jen-Tsan Chi, MD, PhD, Duke University
  Collaborative Research Development Grant
  The Role of Ferroptosis in the Metastatic Ovarian Cancer
• Amrita Salvi, PhD, The University of Illinois at Chicago
  Mentored Investigator Grant
  Investigating the mechanism of action of PHY34 in HGSOC

2021 Grant Recipients

• Melanie Weigert, PhD, University of Chicago
  Mentored Investigator Grant
  Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA
• Sammy Ferri-Borgogno, PhD, MD Anderson Cancer Center
  Mentored Investigator Grant
  Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer
• Benoît Bragantini, PhD, Mayo Clinic
  Mentored Investigator Grant
  Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM
• Ronja Anugwom, PhD, MD Anderson Cancer Center
  Mentored Investigator Grant
  Determine Resistance Mechanisms to ATR Inhibition in Ovarian Cancers
• Arun Kanakkanthara, PhD, Mayo Clinic
  Early Career Investigator Grant
  Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer
• Liya Ding, PhD, Dana Farber Cancer Institute
  Early Career Investigator Grant
  Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer
• Martin Cannon, PhD, University of Arkansas for Medical Sciences
  Collaborative Research Development Grant
  Understanding and Targeting Myeloid Populations in Ovarian Cancer
• Ivan Ahel, PhD, University of Oxford
  Collaborative Research Development Grant
  Exploiting PARP-Modulating Enzymes in Ovarian Cancer Therapy

2020 Grant Recipients

• Elizabeth Lee, MD, Dana Farber Cancer Institute
  Mentored Investigator Grant
  Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies
• Sunila Pradeep, PhD, Medical College of Wisconsin
  Early Career Investigator Grant
  Epigenetic Causes of Acquired Resistance of Anti-VEGF Therapy
• Janice Santiago, PhD, MD Anderson Cancer Center
  Mentored Investigator Grant
  Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
• Morozov Yaroslav, PhD, University of Pennsylvania
  Mentored Investigator Grant
  The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells

2019 Grant Recipients

• Alexander Cole, PhD, Magee-Womens Research Institute
  Mentored Investigator Grant
  Investigating Regulators of Quiescence in Epithelial Ovarian Cancer
• Haineng Xu, PhD, University of Pennsylvania
  Mentored Investigator Grant
  A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers
• Elizabeth Stover, MD, PhD, Dana Farber Cancer Institute
  Early Career Investigator Grant
  Targeting Anti-apoptotic Proteins BCL-XL and MCL-1 in Serous Ovarian Cancer

2018 Grant Recipients

• Damayanti Chakraborty, PhD, Massachusetts General Hospital
  Mentored Investigator Grant
  Understanding Epigenetic Regulation of Copy Number Gains in Ovarian Cancer
• Goldie Lui, PhD, Fred Hutchinson Cancer Research Center
  Mentored Investigator Grant
  Identifying Novel Targeted Therapies for MYC-driven Ovarian Cancer
• Yinu Wang, PhD, Northwestern University
  Mentored Investigator Grant
  Characterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem Cells
• Gordon Mills, MD, PhD, MD Anderson Cancer Center
  Collaborative Research Development Grant
  Rational Combination Therapy in Ovarian Cancer
• Jian Yuan, PhD, Mayo Clinic
  Early Career Investigator Grant
  The Role of BRD9-Rad51 Axis in Chemoresistance in Ovarian Cancer
• David Sabatini, MD, PhD, Whitehead Institute for Biomedical Research
  Collaborative Research Development Grant
  A Personalized Approach to Identify and Target Ovarian Cancer Liabilities

2017 Grant Recipients

• Ilana Chefetz, PhD, University of Michigan
  Early Career Investigator Grant
  Drugs Inducing Necroptotic Cell Death As A New Strategy for High Grade Serous Ovarian Cancer
• Beatrice Rondinelli, PhD, Dana Farber Cancer Institute
  Mentored Investigator Grant
  EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors
• Sunila Pradeep, PhD, Medical College of Wisconsin
  Early Career Investigator Grant
  Epigenetic Causes of Acquired Resistance to Anti-VEGF Therapy

2016 Grant Recipients

• Jill Madden, PhD, Inc., University of Kansas Medical Center Research Institute
  Mentored Investigator Grant
  The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity
• Beth Y. Karlan, MD, Cedars-Sinai Medical Center
  Collaborative Research Development Grant
  Co-Evolution of Epithelial Ovarian Cancer and Tumor Stroma
• Zihua Gong, MD, PhD, MD Anderson Cancer Center
  Early Career Investigator Grant
  DNA Repair Pathways as Target for Therapy-Resistant Ovarian Cancer

2014 Grant Recipients

• Selvendiran Karuppaiyah, PhD, Ohio State University
  Early Career Investigator Grant
  New Type of Experimental Drug for Ovarian Cancer
• S John Weroha, MD, PhD, Mayo Clinic
  Early Career Investigator Grant
  Ovarian Cancer Surrogates to Study Platinum Resistance
• Nima Aghaeepour, PhD, Stanford University
  Mentored Investigator Grant
  Computationally-guided Characterization of Therapy-resistant Ovarian Tumors
• Raphael Ceccaldi, PharmD, PhD, Dana Farber Cancer Institute
  Mentored Investigator Grant
  A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers
• Kyung Hee Noh, PhD, MD Anderson Cancer Center
  Mentored Investigator Grant
  Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer
• Yang Yang, PhD, Yale University
  Mentored Investigator Grant
  P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance
• Yuyu Yuyu, PhD, Johns Hopkins University School of Medicine
  Mentored Investigator Grant
  Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer

2013 Grant Recipients

• Elizabeth Swisher, MD, University of Washington
  Collaborative Research Development Grant
  The FA-BRCA Pathway and Response to Platinum and PARP Inhibitors in Ovarian, Tubal and Peritoneal Carcinomas

2012 Grant Recipients

• Ivan Garcia-Bassets, PhD, University of California - San Diego
  Early Career Investigator Grant
  Targeting the Epigenetic Plasticity of the Platinum Response in Drug-resistant Ovarian Cancer Cells
• W. Ruprecht Wiedemeyer, PhD, Cedars-Sinai Medical Center
  Early Career Investigator Grant
  Ovarian Cancer Evolution After Targeted Therapy

2011 Grant Recipients

• Kenneth Nephew, PhD, Indiana University
  Collaborative Research Development Grant
  A New Approach to Treating Recurrent Ovarian Cancer and Newly Diagnosed Disease
• Weiping Zou, MD, PhD, University of Michigan - Ann Arbor
  Collaborative Research Development Grant
  Understanding how Ovarian Cancer Stem Cells Play a Role in Disease Progression and Drug Resistance
• Analisa DiFeo, PhD, moun, Mount Sinai School of Medicine and Case Western Reserve University
  Early Career Investigator Grant
  What is the Relationship Between an miRNA Molecule and Resistance to Chemotherapy?
• Selvendiran Karuppaiyah, PhD, Ohio State University
  Early Career Investigator Grant
  Safe, Targeted, Antitumor Therapeutics (STAT3 Inhibitors) for Ovarian Cancer
• Mary Zhang, MS, PhD, University South Florida
  Early Career Investigator Grant
  Understanding Mechanisms that Lead to Resistance to Platinum-based Treatments

2009 Grant Recipients

• Anil K. Sood, MD, MD Anderson Cancer Center
  Collaborative Research Development Grant
  Novel Treatments for Ovarian Cancer Using siRNAs

2008 Grant Recipients

• Xiaoping He, MD, PhD, Mayo Clinic Rochester
  Mentored Investigator Grant
  Understanding the Molecular Pathways to Chemotherapy Resistance in Ovarian Cancer

2006 Grant Recipients

• Aliza Leiser, MD, Yale University
  Mentored Investigator Grant
  Clinical Implications of the TLR-4MYD88 Pathway in EOC
• Tsukasa Baba, Duke University
  Mentored Investigator Grant
  Using Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer

2003 Grant Recipients

• Karen M. Vasquez, PhD, MD Anderson Cancer Center
  Individual Investigator Award
  Trying to Understand the Mechanism for Cisplatin
• Parameshwar Mahareshti, DVM, University of Alabama - Birmingham
  Individual Investigator Award
  A New Combination Drug Treatment for Ovarian Cancer
• Kuan-Chun Huang, PhD, Brigham and Women’s Hospital
  Mentored Investigator Grant
  A Possible New Marker for Drug Resistance of Ovarian Cancer
• Thomas Franke, MD, PhD, Columbia University Medical Center
  Individual Investigator Award
  Finding Molecules to Stop an Abnormal Signaling Pathway in Ovarian Cancer

2002 Grant Recipients

• Fergus Couch, PhD, Mayo Clinic
  Individual Investigator Award
  Finding Genes Associated with Drug Resistance in Ovarian Cancer

2001 Grant Recipients

• Rebecca Liu, MD, University of Michigan
  Early Career Investigator Grant
  Dysfunctional Apoptosome Activation in Ovarian Cancer: Implications for Pathogenesis, Prognosis, and Chemoresistance
• Steven W. Johnson, PhD, University of Pennsylvania
  Individual Investigator Award
  Characterizing Differential Gene Expression of Drug Sensitive and Resistant Ovarian Cancer